IPF
Clinical trials for IPF explained in plain language.
Never miss a new study
Get alerted when new IPF trials appear
Sign up with your email to follow new studies for IPF, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill aims to slow deadly lung scarring
Disease control Not yet recruitingThis study tests a new tablet called HSK44459 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 420 adults aged 40 and older will take either the drug or a placebo for a year. The main goal is to see if the dr…
Matched conditions: IPF
Phase: PHASE3 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 11:01 UTC
-
New inhalation drug for lung scarring begins first human safety tests
Knowledge-focused Not yet recruitingThis early-phase study tests the safety and how the body handles a new inhaled drug called RC010 in 42 healthy adults. The drug is being developed for idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The study is not yet recruiting and focuses on side effects…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Nanjing Reju Therapeutics Co., Ltd • Aim: Knowledge-focused
Last updated May 26, 2026 10:54 UTC
-
New IPF drug candidate tested in healthy people for first time
Knowledge-focused Not yet recruitingThis early-stage study tests the safety of a new tablet called HW252001 in 98 healthy adults aged 18 to 55. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The goal is to gather safety information, n…
Matched conditions: IPF
Phase: PHASE1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Knowledge-focused
Last updated May 11, 2026 20:48 UTC